Zaloguj Zarejestruj się zadarmo

Last updated: 23 June 2023 at 4:09pm EST

John Martin Net Worth



John Martin biography

John R. Martin serves as Independent Director of the Company. Mr. Martin served as the President and Chief Executive Officer of Clinical Reference Laboratory from January 2015 to September 2019, having previously served as Executive Vice President and Chief Administrative Officer of Clinical Reference Laboratory from February 2014 to January 2015. Mr. Martin also served as President and Chief Executive Officer of CHC, Inc., the parent company of Clinical Reference Laboratory, from June 2016 to September 2019, in addition to serving as the Chairman of the Board of FormFox, Inc., another subsidiary of CHC, Inc., from August 2016 to September 2019. Prior to joining Clinical Reference Laboratory, Mr. Martin held senior executive roles with Viracor-IBT Laboratories, a clinical diagnostic laboratory specializing in infectious disease and immunology, first as its Chief Financial Officer and then as its President and Chief Executive Officer. Prior to Viracor, Mr. Martin was with George K. Baum & Company, where he served as Managing Director leading the firm’s middle market investment banking and strategic advisory practice. Mr. Martin’s career also includes 11 years in management roles with Sprint Corporation and General Electric. Mr. Martin holds a B.S. in Finance from Kansas State University.

What is the salary of John Martin?

As the Independent Director of Deciphera Pharmaceuticals Inc, the total compensation of John Martin at Deciphera Pharmaceuticals Inc is $218,714. There are 19 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of $9,025,190.



How old is John Martin?

John Martin is 59, he's been the Independent Director of Deciphera Pharmaceuticals Inc since 2015. There are 10 older and 10 younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.

What's John Martin's mailing address?

John's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.

Insiders trading at Deciphera Pharmaceuticals Inc

Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar oraz Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.



What does Deciphera Pharmaceuticals Inc do?

deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.



What does Deciphera Pharmaceuticals Inc's logo look like?

Deciphera Pharmaceuticals Inc logo

Deciphera Pharmaceuticals Inc executives and stock owners

Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: